Agudelo C A, Wise C M
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Curr Opin Rheumatol. 1991 Aug;3(4):684-91. doi: 10.1097/00002281-199108000-00021.
Although our understanding of hyperuricemia and gout has changed little over the past several years, questions remain in defining the many metabolic abnormalities that can result in these problems. In the past year, several papers have further addressed heritable mechanisms for the development of hyperuricemia, as well as environmental factors that contribute to its onset in adulthood. Consequences of hyperuricemia other than clinical gout have received further attention. Although typical gout is easily recognized and treated, several recent papers have addressed atypical presentations of gout, as well as other causes of podagra that might have been attributed previously to gout. The treatment of patients whose disease is uncomplicated by other conditions remains straightforward. However, the presentation of gout in patients with multiple comorbidities not only increases recognition of the toxicity of nonsteroidal anti-inflammatory drugs and colchicine, but often requires innovative approaches to its treatment.
尽管在过去几年里，我们对高尿酸血症和痛风的认识变化不大，但在定义可能导致这些问题的众多代谢异常方面仍存在疑问。在过去的一年里，有几篇论文进一步探讨了高尿酸血症发生发展的遗传机制，以及促成其在成年期发病的环境因素。除临床痛风外，高尿酸血症的其他后果也受到了更多关注。虽然典型痛风很容易识别和治疗，但最近有几篇论文讨论了痛风的非典型表现，以及其他可能曾被归因于痛风的足痛风病因。病情未合并其他疾病的患者的治疗仍然简单直接。然而，痛风在合并多种疾病的患者中的表现不仅增加了对非甾体抗炎药和秋水仙碱毒性的认识，而且往往需要创新的治疗方法。
